Uroxatral ER is a popular brand medicine used in the treatment of BPH. It is composed of active component Alfuzosin Hydrochloride IP. One of the trusted pharmaceutical companies Advanz Pharma manufactures this medicine. It is made available in a dosage of 10 mg and in the form of a conventional tablet.
Manufacturer: Advanz Pharma
Active Ingredient: This given medicine has the main active component Alfuzosin Hydrochloride IP, which is the hydrochloride salt of alfuzosin, a quinazoline compound with smooth muscle-relaxing activity. It binds to and antagonizes post-synaptic alpha-1-adrenoreceptors in the smooth muscle of the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra, initiating relaxation of smooth muscle and resulting in improvement of urine flow and the symptoms of benign prostatic hyperplasia (BPH). It blocks alpha-1-adrenoreceptors in peripheral vascular smooth muscle, leads to vasodilatation and a decrease in peripheral vascular resistance.
Indications: This mentioned medicine is used by men to treat the symptoms of an enlarged prostate BPH. It does not shrink the prostate, but it acts by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently. Uroxatral ER belongs to a class of drugs known as alpha-blockers.
Action Mechanism: Given alpha-blocker medicine, Uroxatral ER exhibits selectivity for alpha1 adrenergic receptors in the lower urinary tract. Blockade of these adrenoreceptors can cause smooth muscle in the bladder neck and prostate to relax, resulting in an improvement in urine flow and a reduction in symptoms of BPH.
Dosages: This alpha-blocker medicine is available for oral consumption and in dosage as mentioned below:
- 10 mg: This tablet shall be consumed once a day after a meal as directed by the doctor
Note: Do not use this medication to treat high blood pressure.